Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Watkins

Showing results (271-280 of 622) with videos related to

Pageof 63
Sort By:
Biophysical Journal|March 25, 2008
Part II: diffraction from two-dimensional cholera toxin crystals bound to their receptors in a lipid monolayerC E Miller, J Majewski, E B Watkins, et al.
Drug Safety|October 30, 2014
Liver safety assessment in special populations (hepatitis B, C, and oncology trials)Gerd A Kullak-Ublick, Michael Merz, Louis Griffel, et al.
Drug Safety|March 2, 2018
Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial ExperienceJohn F Marcinak, Melvin S Munsaka, Paul B Watkins, et al.
Medical Care|September 1, 2016
Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and ExpendituresKai Yeung, Anirban Basu, Ryan N Hansen, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 22, 2007
Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicityElaine M Leslie, Paul B Watkins, Richard B Kim, et al.
Drug Safety|October 18, 2018
Correction to: Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial ExperienceJohn F Marcinak, Melvin S Munsaka, Paul B Watkins, et al.
Gastroenterology|December 1, 1980
Liver in the cerebro-hepato-renal syndrome: defective bile acid synthesis and abnormal mitochondriaR K Mathis, J B Watkins, P Szczepanik-Van Leeuwen, et al.
Clinical Pharmacology and Therapeutics|August 5, 2020
Quantitative Systems Toxicology Modeling Predicts that Reduced Biliary Efflux Contributes to Tolvaptan HepatotoxicityJames J Beaudoin, William J Brock, Paul B Watkins, et al.
Planta|September 24, 2005
Isolation and characterization of a lipid transfer protein expressed in ripening fruit of Capsicum chinenseKede Liu, Hui Jiang, Shanna L Moore, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|June 2, 2026
Intramolecular Interactions between Folded and Disordered Regions Shape Ubiquilin Structure and FunctionJessica K Niblo, Nirbhik Acharya, Maxwell B Watkins, et al.
Pageof 63

Showing results (271-280 of 622) with videos related to

Sort By:
Pageof 63
Biophysical Journal|March 25, 2008
Part II: diffraction from two-dimensional cholera toxin crystals bound to their receptors in a lipid monolayerC E Miller, J Majewski, E B Watkins, et al.
Drug Safety|October 30, 2014
Liver safety assessment in special populations (hepatitis B, C, and oncology trials)Gerd A Kullak-Ublick, Michael Merz, Louis Griffel, et al.
Drug Safety|March 2, 2018
Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial ExperienceJohn F Marcinak, Melvin S Munsaka, Paul B Watkins, et al.
Medical Care|September 1, 2016
Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and ExpendituresKai Yeung, Anirban Basu, Ryan N Hansen, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 22, 2007
Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicityElaine M Leslie, Paul B Watkins, Richard B Kim, et al.
Drug Safety|October 18, 2018
Correction to: Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial ExperienceJohn F Marcinak, Melvin S Munsaka, Paul B Watkins, et al.
Gastroenterology|December 1, 1980
Liver in the cerebro-hepato-renal syndrome: defective bile acid synthesis and abnormal mitochondriaR K Mathis, J B Watkins, P Szczepanik-Van Leeuwen, et al.
Clinical Pharmacology and Therapeutics|August 5, 2020
Quantitative Systems Toxicology Modeling Predicts that Reduced Biliary Efflux Contributes to Tolvaptan HepatotoxicityJames J Beaudoin, William J Brock, Paul B Watkins, et al.
Planta|September 24, 2005
Isolation and characterization of a lipid transfer protein expressed in ripening fruit of Capsicum chinenseKede Liu, Hui Jiang, Shanna L Moore, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|June 2, 2026
Intramolecular Interactions between Folded and Disordered Regions Shape Ubiquilin Structure and FunctionJessica K Niblo, Nirbhik Acharya, Maxwell B Watkins, et al.
Pageof 63